136790-76-6
Chemical Structure
Lubiprostone
Synonym(s): RU-0211; SPI-0211
- CAS No.: 136790-76-6
- Formula:C20H32F2O5
- Molecular Weight:390.46
IUPAC Name: 7-((1R,2R,3R)-2-(4,4-difluoro-3-oxooctyl)-3-hydroxy-5-oxocyclopentyl)heptanoic acid
InChIKey: DBVFKLAGQHYVGQ-BFYDXBDKSA-N
SMILES: O=C(C(F)(F)CCCC)CC[C@@H]([C@@H](C1)O)[C@H](C1=O)CCCCCCC(O)=O
Biological Activity: Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Lubiprostone | 99.09% | Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lubiprostone (Standard) | ≥98% | Lubiprostone (Standard) is the analytical standard of Lubiprostone. This product is intended for research and analytical applications. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Lubiprostone-d7 | Lubiprostone-d7 (RU-0211-d7) is the deuterium labeled Lubiprostone. Lubiprostone (SPI-0211) increases intestinal fluid secretion through generation of CIC-2/CFTR and activation of cAMP signaling pathway. Lubiprostone inhibits myeloperoxidase (MPO) activity, downregulates Indomethacin (HY-14397)-induced iNOS and TNFα expression. Lubiprostone can be used for chronic constipation research. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Ao M, et al., Lubiprostone activates Cl- secretion via cAMP signaling and increases membrane CFTR in the human colon carcinoma cell line, T84. Dig Dis Sci. 2011 Feb;56(2):339-51. [Content Brief]
- [2]. Kim MY, et al., Lubiprostone significantly represses fatty liver diseases via induction of mucin and HDL release in mice. Life Sci. 2022 Dec 15;311(Pt A):121176. [Content Brief]
- [3]. Hayashi S, et al., Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. J Pharmacol Exp Ther. 2014 Jun;349(3):470-9. [Content Brief]
